Antimalarial Drug Resistance in Africa: Strategies for Monitoring and Deterrence

  • C. V. Plowe
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 295)


Despite the initiation in 1998 by the World Health Organization of a campaign to ‘Roll Back Malaria’, the rates of disease and death caused by Plasmodium falciparum malaria in sub-Saharan Africa are growing. Drug resistance has been implicated as one of the main factors in this disturbing trend. The efforts of international agencies, governments, public health officials, advocacy groups and researchers to devise effective strategies to deter the spread of drug resistant malaria and to ameliorate its heavy burden on the people of Africa have not succeeded. This review will not attempt to describe the regional distribution of drug resistant malaria in Africa in detail, mainly because information on resistance is limited and has been collected using different methods, making it difficult to interpret. Instead, the problems of defining and monitoring resistance and antimalarial drug treatment outcomes will be discussed in hopes of clarifying the issues and identifying ways to move forward in a more coordinated fashion. Strategies to improve measurement of resistance and treatment outcomes, collection and use of information on resistance, and potential approaches to deter and reduce the impact of resistance, will all be considered. The epidemiological setting and the goals monitoring determine how antimalarial treatment responses should be measured. Longitudinal studies, with incidence of uncomplicated malaria episodes as the primary endpoint, provide the best information on which to base treatment policy changes, while simpler standard in vivo efficacy studies are better suited for ongoing efficacy monitoring. In the absence of an ideal antimalarial combination regimen, different treatment alternatives are appropriate in different settings. But where chloroquine has failed, policy changes are long overdue and action must be taken now.


Plasmodium Falciparum Antimalarial Drug Falciparum Malaria Severe Malaria Artemisinin Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agarwal A, Guindo A, Cissoko, Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D (2000) Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood 96:2358–2363Google Scholar
  2. Attaran A, Barnes KI, Curtis C, D’Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape J, Watkins WM (2004) WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363:237–240PubMedCrossRefGoogle Scholar
  3. Baird JK, Purnomo, Basri H, Bangs MJ, Andersen EM, Jones TR, Masbar S, Harjosuwarno S, Subianto B, Arbani PR (1993) Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J Trop Med Hyg 49:707–719PubMedGoogle Scholar
  4. Bloland PB (2001) Drug resistance in malaria. WHO/CDS/CSR/DRS/2001.4. Geneva, WHO Department of Communicable Disease Surveillance and ResponseGoogle Scholar
  5. Bloland PB, Ettling M (1999) Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 93:5–23PubMedCrossRefGoogle Scholar
  6. Bloland PB, Ettling M, Meek S (2000) Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 78:1378–1388PubMedGoogle Scholar
  7. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC (1993) Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167:932–937PubMedGoogle Scholar
  8. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE (1994) Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224:397–405PubMedCrossRefGoogle Scholar
  9. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: Comparison of results based on genotyping of MSP-1, MSP-2, and GLURP. Am J Trop Med Hyg 68:133–139PubMedGoogle Scholar
  10. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85:9109–9113PubMedGoogle Scholar
  11. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV (2001a) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257–263PubMedCrossRefGoogle Scholar
  12. Djimde A, Doumbo OK, Steketee RW, Plowe CV (2001b) Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358:890–891PubMedCrossRefGoogle Scholar
  13. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV (2003) Clearance of drug resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69:558–563PubMedGoogle Scholar
  14. Dorsey G, Kamya MR, Singh A, Rosenthal PJ (2001) Polymorphisms in the Plasmodium falciparum PfCRT and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 183:1417–1420PubMedCrossRefGoogle Scholar
  15. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: A longitudinal randomised trial. Lancet 360:2031–2038PubMedCrossRefGoogle Scholar
  16. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC (2000) The tyrosine-86 allele of the PfMDR1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 108:13–23PubMedCrossRefGoogle Scholar
  17. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sihdu AB, Naude B, Deitsch KW, Su X, Wootton JC, Roepe PD, Wellems TE (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6:861–871PubMedCrossRefGoogle Scholar
  18. Fidock DA, Nomura T, Wellems TE (1998) Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 54:1140–1147PubMedGoogle Scholar
  19. Fidock DA, Wellems, TE (1997) Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 94:10931–10936PubMedCrossRefGoogle Scholar
  20. Foote SJ, Cowman, AF (1994) The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop 56:157–171PubMedGoogle Scholar
  21. Foote SJ, Galatis D, Cowman AF (1990) Amino acids in the dihydrofolate reductasethymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87:3014–3017PubMedGoogle Scholar
  22. Greenberg AE, Ntumbanzondo M, Ntula N, Mawa L, Howell J, Davachi F (1989) Hospital-based surveillance of malaria-related paediatric morbidity and mortality in Kinshasa, Zaire. Bull World Health Organ 67:189–196PubMedGoogle Scholar
  23. Hastings IM (1997) A model for the origins and spread of drug-resistant malaria. Parasitology 115:133–141PubMedCrossRefGoogle Scholar
  24. Hastings IM Mackinnon MJ (1998) The emergence of drug-resistant malaria. Parasitology 117:411–417PubMedCrossRefGoogle Scholar
  25. Hellgren U, Kihamia CM, Mahikwano LF, Bjorkman A, Eriksson O, Rombo L (1989) Response of Plasmodium falciparum to chloroquine treatment: Relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull World Health Organ 67:197–202PubMedGoogle Scholar
  26. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352:595–600PubMedGoogle Scholar
  27. Jelinek T, Aida AO, Peyerl-Hoffmann G, Jordan S, Mayor A, Heuschkel C, el Valy AO, von Sonnenburg F, Christophel EM (2002) Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in Southern Mauritania. Am J Trop Med Hyg 67:449–453PubMedGoogle Scholar
  28. Koella JC Antia R (2003) Epidemiological models for the spread of anti-malarial resistance. Malar J 2:3PubMedCrossRefGoogle Scholar
  29. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV (2003) Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187:1870–1875PubMedCrossRefGoogle Scholar
  30. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum Malaria. J Infect Dis 185:380–388PubMedCrossRefGoogle Scholar
  31. Lim AS, Galatis D, Cowman AF. (1996). Plasmodium falciparum: amplification and overexpression of PfMDR1 is not necessary for increased mefloquine resistance. Exp Parasitol. 83:295–303PubMedGoogle Scholar
  32. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maelankirri L, Chongsuphajaisiddhi T, Nosten F (1996) The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 90:105–111PubMedCrossRefGoogle Scholar
  33. Mackinnon MJ (1997) Survival probability of drug resistant mutants in malaria parasites. Proc Roy Soc Lond—Series B: Biological Sciences 264:53–59Google Scholar
  34. Mayor AG, Gomez-Olive X, Aponte JJ, Casimiro S, Mabunda S, Dgedge M, Barreto A, Alonso PL (2001) Prevalence of the K76T mutation in the putative Plasmodium falciparum chloroquine resistance transporter (PfCRT) gene and its relation to chloroquine resistance in Mozambique. J Infect Dis 183:1413–1416PubMedCrossRefGoogle Scholar
  35. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, White NJ (2001) Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 65:918–923PubMedGoogle Scholar
  36. Meshnick SR (2002) Artemisinin: Mechanisms of action, resistance and toxicity. Int J Parasitol 32:1655–1660PubMedGoogle Scholar
  37. Miller LH, Carter R (1976) A review. Innate resistance in malaria. Exp Parasitol 40:132–146PubMedCrossRefGoogle Scholar
  38. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi N, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A (2003) Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transportergene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 68:413–415PubMedGoogle Scholar
  39. Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, Rastrelli E, Olivieri A, Calissano C, Paganotti GM, D’Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M (2001) Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 414:305–308PubMedCrossRefGoogle Scholar
  40. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, Cooper RA, Wootton JC, Xiong M, Su XZ. (2003). Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 49:977–989PubMedCrossRefGoogle Scholar
  41. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W (2001a) Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358:1218–1223PubMedCrossRefGoogle Scholar
  42. Mutabingwa TK, Maxwell CA, Sia IG, Msuya FH, Mkongewa S, Vannithone S, Curtis J, Curtis CF (2001b) A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans R Soc Trop Med Hyg 95:433–438PubMedCrossRefGoogle Scholar
  43. Nguyen-Dinh, P Payne D (1980) Pyrimethamine sensitivity in Plasmodium falciparum: Determination in vitro by a modified 48-hour test. Bull World Health Organ 58:909–912PubMedGoogle Scholar
  44. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ (1991) Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337:1140–1143PubMedCrossRefGoogle Scholar
  45. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW (1998) Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 59:813–822PubMedGoogle Scholar
  46. Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, Day KP (1995) Mating patterns in malaria parasite populations of Papua New Guinea. Science 269:1709–1711PubMedGoogle Scholar
  47. Peel SA, Bright P, Yount B, Handy J, Baric RS. (1994). A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 51:648–658PubMedGoogle Scholar
  48. Peterson DS, Milhous WK, Wellems TE (1990) Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87:3018–3022PubMedGoogle Scholar
  49. Peterson DS, Walliker D, Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85:9114–9118PubMedGoogle Scholar
  50. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S, Zhong K, Kain KC (2001) Plasmodium falciparum malaria in Laos: Chloroquine treatment outcome and predictive value of molecular markers. J Infect Dis 183:789–795PubMedCrossRefGoogle Scholar
  51. Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, Coulibaly D, Thera M, Wellems TE, Diallo DA (2001) Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: Parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 64:242–246PubMedGoogle Scholar
  52. Plowe CV. (2003). Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol 206:3745–3752.PubMedCrossRefGoogle Scholar
  53. Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, Taylor TE (2004) Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: Five year prospective study. Br Med J 328:545–548Google Scholar
  54. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S (1999) The PfMDR1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 43:2943–2949PubMedGoogle Scholar
  55. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347:1654–1658PubMedCrossRefGoogle Scholar
  56. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF (2000) Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906–909PubMedGoogle Scholar
  57. Ritchie GY, Mungthin M, Green JE, Bray PG, Hawley SR. Ward SA. (1996). In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Mol Biochem Parasitol 83:35–46PubMedCrossRefGoogle Scholar
  58. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B (2003) Antifolate antimalarial resistance in southeast Africa: A population-based analysis. Lancet 361:1174–1181PubMedCrossRefGoogle Scholar
  59. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peshu N (1995) Natural selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376:246–249PubMedCrossRefGoogle Scholar
  60. Sidhu AB, Verdier-Pinard D, Fidock DA (2002) Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by PfCRT mutations. Science 298:210–213PubMedCrossRefGoogle Scholar
  61. Srivastava IK Vaidya AB (1999) A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43:1334–1339PubMedGoogle Scholar
  62. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, Winstanley PA (2002) Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: A randomised clinical trial. Lancet 360:1136–1143PubMedCrossRefGoogle Scholar
  63. Trape JF, Pison G, Preziosi MP, Enel C, Dulou AD, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F (1998) Impact of chloroquine resistance on malaria mortality. Comptes Rendus de l’Academie des Sciences de Paris / Life Sciences 321:689–697Google Scholar
  64. van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM (1995) Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 89:672–676PubMedGoogle Scholar
  65. Viriyakosol S, Siripoon N, Petcharapirat C, Petcharapirat P, Jarra W, Brown KN, Snounou G (1995) Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull World Health Organ 73:85–95PubMedGoogle Scholar
  66. Walker DJ, Pitsch JL, Peng MM, Robinson BL, Peters W, Bhisutthibhan J, Meshnick SR (2000) Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob Agents Chemother 44:344–347PubMedCrossRefGoogle Scholar
  67. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK (1990) Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 84:492–495PubMedCrossRefGoogle Scholar
  68. Wellems TE, Plowe CV (2001) Chloroquine-resistant malaria. J Infect Dis 184:770–776PubMedCrossRefGoogle Scholar
  69. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18:458–464PubMedCrossRefGoogle Scholar
  70. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, Danis M, Greenwood BM, Anderson RM, Olliaro P (1999) Averting a malaria disaster. Lancet 353:1965–1967PubMedCrossRefGoogle Scholar
  71. WHO (1973) Chemotherapy of malaria and resistance to antimalarials. 529. World Health Organization, Geneva. WHO Technical Report SeriesGoogle Scholar
  72. WHO (1996) Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Geneva, World Health Organization, Division of Control of Tropical DiseasesGoogle Scholar
  73. WHO (2002) Monitoring antimalarial drug resistance. Bloland PB, D’Alessandro, Ringwald, and Watkins. WHO/CDS/CSR/EPH/2002.17. Geneva, World Health OrganizationGoogle Scholar
  74. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, Milhous WK, Wirth DF (1993) Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 57:151–160PubMedCrossRefGoogle Scholar
  75. Winstanley PA (2000) Chemotherapy for falciparum malaria: The armoury, the problems and the prospects. Parasitol Today 16:146–153PubMedCrossRefGoogle Scholar
  76. Wolday D, Kibreab T, Bukenya D, Hodes R(1995) Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 89:654–656PubMedCrossRefGoogle Scholar
  77. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF (1998) Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: Evidence for quinine resistance. Am J Trop Med Hyg 58:630–637PubMedGoogle Scholar
  78. Zolg JW, Plitt JR, Chen GX, Palmer S (1989) Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253–262PubMedCrossRefGoogle Scholar
  79. Zucker JR, Lackritz EM, Ruebush TK, Hightower AW, Adungosi JE, Were JB, Metchock B, Patrick E, Campbell CC (1996) Childhood mortality during and after hospitalization in western Kenya: Effect of malaria treatment regimens. Am J Trop Med Hyg 55:655–660PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • C. V. Plowe
    • 1
  1. 1.Malaria Section, Center for Vaccine DevelopmentUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations